Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRACTION-Gastric Cancer: Phase 2 Real-time Assessment of Nivolumab Combination Therapies
2016-002807-24Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of nivolumab in gastric cancer (GC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Objective Response Rate. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2016-002807-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002807-24.